.jpg "H.C. Wainwright Thinks Asterias Biotherapeutics")
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST), with a price target of $11. The company’s shares closed yesterday at $1.25, close to its 52-week low of $1.20.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.3% and a 35.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Asterias Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.
Find more picks by Best Performing Analysts >>
Based on Asterias Biotherapeutics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $28K and GAAP net loss of $6.55 million. In comparison, last year the company earned revenue of $2.01 million and had a GAAP net loss of $6.29 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.
